A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Poseltinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RAjuvenate
- Sponsors Eli Lilly
- 17 Apr 2018 This trial has been discontinued in Poland.
- 09 Mar 2018 Planned End Date changed from 1 May 2019 to 1 Mar 2019.
- 09 Mar 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2018.